Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.
June 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” ILC1-like cells can cause alopecia areata by attacking hair follicles.
ILC1-like cells can independently cause alopecia areata by affecting hair follicles.
27 citations,
April 2018 in “Journal of autoimmunity” iNKT cells can help prevent and treat alopecia areata by promoting hair regrowth.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
55 citations,
October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
12 citations,
May 2017 in “Pharmacology & therapeutics” Targeting immune tolerance issues in Alopecia Areata could restore hair growth and maintain remission.
60 citations,
September 2015 in “Expert Review of Clinical Immunology” Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
64 citations,
July 2016 in “Journal of Immunology” Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.
148 citations,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
57 citations,
April 2019 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata involves immune system imbalances that may lead to depression and anxiety.
1 citations,
September 2023 in “Clinical, cosmetic and investigational dermatology” Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.
April 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” 6.1% of patients seeking PRP for hair loss had undiagnosed cicatricial alopecia, which PRP cannot treat.
April 2021 in “Journal of Investigative Dermatology” An AI photographic device effectively tracked hair growth improvements in women treated for hair loss.
9 citations,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
February 2021 in “Journal of pharmaceutical and biological sciences” No cure exists for alopecia areata, and treatments are personalized.
July 2018 in “British Journal of Dermatology” Hair regrowth was seen in 83% of children with alopecia, immune system plays a role in the condition, and various treatments showed effectiveness for hair and nail disorders.
70 citations,
February 2015 in “Expert Opinion on Drug Discovery” Topical drugs and near-infrared light therapy show potential for treating alopecia.
January 2017 in “Journal of Investigative Dermatology Symposium Proceedings” The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.
2 citations,
November 2023 in “Frontiers in microbiology” The health of the gut may be important in developing new ways to prevent, diagnose, and treat alopecia areata.
2 citations,
January 2017 in “Clinical and medical investigations” Herbal lotions are effective for severe hair loss, with a 64.8% success rate, but relapse is common and long-term management requires allergen control and possible corticosteroid use.
15 citations,
December 2018 in “International journal of environmental research and public health/International journal of environmental research and public health” EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.
6 citations,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” The study suggests that a specific type of immune cell, memory-like NK cells, may increase during active hair loss in Alopecia areata.
July 2023 in “The Egyptian Journal of Hospital Medicine ” Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
6 citations,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.
701 citations,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
3 citations,
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” ILC1 cells contribute to hair loss in alopecia areata.
January 2018 in “Elsevier eBooks” The document concludes that alopecia has significant social and psychological effects, leading to a market for hair loss treatments.